Press Release

IQVIA Launches OCE+ To Deliver Enhanced AI-Driven Customer Engagement

Μαρ 15, 2022

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- IQVIA™ (NYSE:IQV) today announced the launch of OCE+, the first of several new advancements to its leading life science customer engagement platform. OCE+ adds IQVIA’s Next Best recommendation engine – a daily workflow tool providing AI-driven recommendations for engaging healthcare professionals (HCP) – to its Orchestrated Customer Engagement (OCE) platform, providing enhanced HCP experiences, improved productivity, and increased ROI.

OCE+ uses IQVIA’s industry-leading data and advanced analytics to deliver AI-driven recommendations directly into the daily workflows of life sciences commercial teams. This provides commercial teams with HCP-specific actions to take, such as recommending the best time to engage and the best method of contact. Recommendations are delivered directly through the OCE platform, providing a simplified and seamless user experience.

“The ability to use and harmonize data across different networks and systems continues to be a key challenge in the healthcare industry. IQVIA is uniquely positioned to bring together data, analytics, technology, and AI/ML capabilities all under one roof,” said Sanjay Chikarmane, chief product officer, IQVIA. “With OCE+, our customers can make smarter and more informed decisions through embedded intelligence that surfaces the actionable insights they need, when they need them, to better personalize the HCP experience and improve business results.”

The seamless out-of-the-box integration of the OCE platform with the Next Best recommendation engine provides flexible and scalable access to meet all customer engagement needs. Users will find the workflow notifications easy-to-use with tailored recommendations based on contextual needs and clear rationale. Users can also reply with direct feedback to those notices to further fine tune insights. By enabling commercial teams with AI-powered personalization, decisions can be made with greater speed, accuracy, and confidence to improve the HCP experience and yield best results.

“A key part of an effective customer engagement is orchestration, enabling more visibility into interaction history and customer preferences,” said Michael Townsend, research director, Life Sciences Commercial Strategies at leading industry analysis firm, IDC. “Utilizing an integrated AI engine to provide users not just with deep insights in real time, but with actionable behavior-changing recommendations, will be a differentiator and provide real value to the industry.”

To learn more about IQVIA OCE+, visit and/or tune into IQVIA Technologies at HIMSS 2022 March 14-18, or click here.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 79,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

Nick Childs, IQVIA Investor Relations (nick.childs@iqvia.com)
+1.973.316.3828

Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com)
+1.484.567.6732

Source: IQVIA

Contact Us